当前位置: 首页 >> 检索结果
4541. Letter by Mamdooh et al Regarding Article, "Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis".
作者: Hazem Mamdooh.;Francesco Pollari.;Theodor Fischlein.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011839页 4542. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.
作者: Benjamin E Peterson.;Robert A Harrington.;Gregg W Stone.;Ph Gabriel Steg.;C Michael Gibson.;Christian W Hamm.;Matthew J Price.;Renato D Lopes.;Sergio Leonardi.;Jayne Prats.;Efthymios N Deliargyris.;Kenneth W Mahaffey.;Harvey D White.;Deepak L Bhatt.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011069页
In randomized trials, cangrelor reduced periprocedural ischemic events related to percutaneous coronary intervention without increasing GUSTO severe bleeding. However, some antiplatelet agents have shown a differential treatment effect by body mass index (BMI).
4543. Response by Vilalta et al to Letter Regarding Article, "Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis".
作者: Victoria Vilalta.;Germán Cediel.;Siamak Mohammadi.;Antoni Bayés-Genis.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011850页 4545. Contemporary Costs Associated With Transcatheter Versus Surgical Aortic Valve Replacement in Medicare Beneficiaries.
作者: Suzanne J Baron.;Michael P Ryan.;Kimberly A Moore.;Seth J Clancy.;Candace L Gunnarsson.
来源: Circ Cardiovasc Interv. 2022年15卷3期e011295页
In patients with severe aortic stenosis, treatment with transcatheter aortic valve replacement (TAVR) has been shown to be cost-effective in the high-risk surgical population and cost-saving in the intermediate-risk population when compared with surgical aortic valve replacement (SAVR) in early pivotal clinical trials. Whether TAVR is associated with comparable or lower costs when compared with SAVR in contemporary clinical practice is unknown.
4547. Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication.
作者: Atsushi Sugiura.;Refik Kavsur.;Maximilian Spieker.;Christos Iliadis.;Tadahiro Goto.;Can Öztürk.;Marcel Weber.;Noriaki Tabata.;Sebastian Zimmer.;Jan-Malte Sinning.;Victor Mauri.;Patrick Horn.;Malte Kelm.;Stephan Baldus.;Georg Nickenig.;Ralf Westenfeld.;Roman Pfister.;Marc Ulrich Becher.
来源: Circ Cardiovasc Interv. 2022年15卷3期e010895页
Recurrent mitral regurgitation (MR) following MitraClip has not been thoroughly investigated. We aimed to examine the predictive factors, morphology, and long-term outcome of recurrent MR after MitraClip.
4548. Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
作者: Ivana Semova.;Amy E Levenson.;Joanna Krawczyk.;Kevin Bullock.;Mary E Gearing.;Alisha V Ling.;Kathryn A Williams.;Ji Miao.;Stuart S Adamson.;Dong-Ju Shin.;Satyapal Chahar.;Mark J Graham.;Rosanne M Crooke.;Lee R Hagey.;David Vicent.;Sarah D de Ferranti.;Srividya Kidambi.;Clary B Clish.;Sudha B Biddinger.
来源: Circulation. 2022年145卷13期969-982页
The risk of cardiovascular disease in type 1 diabetes remains extremely high, despite marked advances in blood glucose control and even the widespread use of cholesterol synthesis inhibitors. Thus, a deeper understanding of insulin regulation of cholesterol metabolism, and its disruption in type 1 diabetes, could reveal better treatment strategies.
4550. Rare Cause of Acute Myocardial Infarction in Children: Congenital Hypoplastic Left Coronary Cusp Associated With a Small Opening Into the Left Coronary Sinus.
作者: Hien S Nguyen.;Manh T Tran.;Hanh D Nguyen.;Ngoc M Nguyen.;Long D Tran.;Hung Q Nguyen.
来源: Circ Cardiovasc Imaging. 2022年15卷3期e013900页 4551. Response by Kremer et al to Letter Regarding Article, "Acute Impact of Prone Positioning on the Right Ventricle in COVID-19-Associated Acute Respiratory Distress Syndrome".4553. Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis.
作者: Jin-Kai Wang.;Yang Li.;Xiao-Lu Zhao.;Yuan-Bin Liu.;Jing Tan.;Yu-Ying Xing.;Dilare Adi.;Yong-Tao Wang.;Zhen-Yan Fu.;Yi-Tong Ma.;Song-Mei Liu.;Yong Liu.;Yan Wang.;Xiong-Jie Shi.;Xiao-Yi Lu.;Bao-Liang Song.;Jie Luo.
来源: Circulation. 2022年145卷9期675-687页
High blood cholesterol accelerates the progression of atherosclerosis, which is an asymptomatic process lasting for decades. Rupture of atherosclerotic plaques induces thrombosis, which results in myocardial infarction or stroke. Lowering cholesterol levels is beneficial for preventing atherosclerotic cardiovascular disease.
4554. Transcatheter Mitral Intervention Relieves Dynamic Outflow Obstruction and Reduces Cardiac Workload in Hypertrophic Cardiomyopathy.
作者: Carey Kimmelstiel.;Kay D Everett.;Pankaj Jain.;Satoshi Miyashita.;Richard Botto.;Charles Resor.;Ethan Rowin.;Martin Maron.;Navin K Kapur.
来源: Circ Heart Fail. 2022年15卷4期e009171页 4555. Peripheral Venous Pressure-Assisted Exercise Stress Echocardiography in the Evaluation of Pulmonary Hypertension During Exercise in Patients With Suspected Heart Failure With Preserved Ejection Fraction.
作者: Jeong Hoon Yang.;Tomonari Harada.;Ki Hong Choi.;Toshimitsu Kato.;Darae Kim.;Noriaki Takama.;Taek Kyu Park.;Masahiko Kurabayashi.;Sung-A Chang.;Masaru Obokata.
来源: Circ Heart Fail. 2022年15卷3期e009028页
Identification of elevated pulmonary artery (PA) pressures during exercise may provide diagnostic, prognostic, and therapeutic implications in heart failure with preserved ejection fraction. Although widely performed, exercise stress echocardiography may underestimate true PA pressures due to the difficulty in estimating right atrial pressure (RAP) during exercise. We hypothesized that peripheral venous pressure (PVP) could allow for reliable estimation of RAP, and thus PA pressures during exercise stress echocardiography.
4556. Strategies to Reduce Low-Value Cardiovascular Care: A Scientific Statement From the American Heart Association.
作者: Vinay Kini.;Khadijah Breathett.;Peter W Groeneveld.;P Michael Ho.;Brahmajee K Nallamothu.;Pamela N Peterson.;Pam Rush.;Tracy Y Wang.;Emily P Zeitler.;William B Borden.; .
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷3期e000105页
Low-value health care services that provide little or no benefit to patients are common, potentially harmful, and costly. Nearly half of the patients in the United States will receive at least 1 low-value test or procedure annually, creating risk of avoidable complications from subsequent cascades of care and excess costs to patients and society. Reducing low-value care is of particular importance to cardiovascular health given the high prevalence and costs of cardiovascular disease in the United States. This scientific statement describes the current scope and impact of low-value cardiovascular care; reviews existing literature on patient-, clinician-, health system-, payer-, and policy-level interventions to reduce low-value care; proposes solutions to achieve meaningful and equitable reductions in low-value care; and suggests areas for future research priorities.
|